Stockscreener 앱 받기
1.86
6.29%
0.11
시간 외 거래:
1.86
전일 마감가:
$1.75
열려 있는:
$1.75
하루 거래량:
2.13M
Relative Volume:
0.74
시가총액:
$788.05M
수익:
$49.80M
순이익/손실:
$-50.34M
주가수익비율:
-13.40
EPS:
-0.1388
순현금흐름:
$-67.85M
1주 성능:
+11.38%
1개월 성능:
+10.06%
6개월 성능:
+21.57%
1년 성능:
+263.21%
1일 변동 폭
$1.74
$1.86
1주일 범위
$1.65
$1.86
52주 변동 폭
$0.48
$1.86
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.86 | 741.44M | 49.80M | -50.34M | -67.85M | -0.1388 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals Q2 2025 Earnings Preview - MSN
Growth Report: What is the target price for Lexicon Pharmaceuticals Inc stock2026 Update & Weekly High Return Opportunities - baoquankhu1.vn
IPO Launch: Is Lexicon Pharmaceuticals Inc stock trending bullish2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
LXRX SEC FilingsLexicon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
LXRX stock up as NVO initiates phase I study of partnered obesity drug - MSN
Buyback Watch: Can Lexicon Pharmaceuticals Inc reach all time highs this year2026 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - Yahoo Finance UK
Lexicon Pharmaceuticals (LXRX) price target increased by 15.07% to 3.43 - MSN
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions - Yahoo Finance
LXRX Technical Analysis & Stock Price Forecast - Intellectia AI
Lexicon Pharmaceuticals, Inc. (LX31.MU) stock price, news, quote and history - Yahoo Finance UK
Lexicon Pharmaceuticals joins Texas Life Sciences Summit to engage industry leaders and drive sector momentum - Traders Union
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% HigherTime to Buy? - MarketBeat
Certain Stock Options of Lexicon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Restricted Stock Units of Lexicon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Lexicon Pharmaceuticals unveils ACC26 trial analysis on BMI and cardiovascular outcomes - Traders Union
Published on: 2026-03-29 16:03:42 - baoquankhu1.vn
Lexicon Pharmaceuticals unveils new SOTA‑P‑CARDIA Chapter 2 data in HFpEF at ACC26 - Traders Union
Lexicon Pharmaceuticals Stock: Pipeline Progress and Financial Strategy in Biopharma Sector - AD HOC NEWS
ACC meeting features Lexicon Pharmaceuticals clinical research presentations - Traders Union
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug - Yahoo Finance
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo - Bitget
Lexicon brings ACC data showing heart benefits across BMI groups - Stock Titan
Lexicon Pharmaceuticals (LXRX) Receives Reiterated Buy Rating at $6.00 | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright - marketbeat.com
Novo Nordisk Begins Study of Lexicon Oral Obesity Drug - wsj.com
Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851 - TradingView
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 - Yahoo Finance
A new obesity pill enters human testing, triggering $10M for Lexicon - Stock Titan
HC Wainwright remains a buy on Lexicon Pharmaceuticals (LXRX) - MSN
Published on: 2026-03-22 17:56:17 - baoquankhu1.vn
LXRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
Lexicon Pharmaceuticals advances chronic pain treatment options with focus on non opioid innovation - Traders Union
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - MSN
Lexicon Pharma spikes after insider buy - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Growth Value: How does Lexicon Pharmaceuticals Inc compare to its peers2026 EndofMonth & Low Drawdown Investment Ideas - baoquankhu1.vn
Dip Buying: How much upside does Lexicon Pharmaceuticals Inc have2026 PreEarnings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
HC Wainwright raises its price target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and maintains a buy rating - MSN
Lexicon Pharmaceuticals, Inc.Common Stock (NQ: LXRX - The Chronicle-Journal
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):